Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

For this study, participants ages 6-65 years, who have atopic dermatitis and don't have any of the exclusion criteria will be invited to participate in the study. There will be a 1 time visit where questionnaires, blood draw, skin swab and skin biopsies will be performed.

Inclusion criteria

• Male or female participants ≥6 to 65 yrs of age
• Meet AD Standard Diagnostic Criteria

Exclusion criteria

• Enrollment in another clinical trial
• Hypersensitivity to an agent used for the skin decolonization protocol
• Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, JAK inhibitors, azathioprine, methotrexate)
• Phototherapy for AD within 4 weeks
• Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks
• Use of topical steroids, topical calcineurin inhibitors or crisaborale within 7 days
• Bleach baths within 7 days of the first Visit
• Use of oral or topical antibiotics within 21 days of the beginning of the study
• Asthmatics receiving more than 500 μg per day of inhaled corticosteroids
• History of (HIV, hepatitis B, hepatitis C, tuberculosis malignancy
• Skin comorbidities that may interfere with assessments: psoriasis, cutaneous T Cell lymphoma,,
• Severe ongoing medical illnesses e.g. cardiovascular, renal disease, autoimmune disease.
• Febrile illness at time of visits
• Suspected immune deficiency or family history of primary immunodeficiency